Last reviewed · How we verify
PD P 506 A
PD P 506 A is a Small molecule drug developed by photonamic GmbH & Co. KG. It is currently in Phase 2 development. Also known as: Alacare®.
PD P 506 A is a small molecule used in the treatment of onychomycosis, actinic keratosis, and actinic keratoses. It is administered as part of photodynamic therapy, which may also be combined with cryosurgery in some cases.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PD P 506 A |
|---|---|
| Also known as | Alacare® |
| Sponsor | photonamic GmbH & Co. KG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities (PHASE2)
- Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail. (PHASE2)
- PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK (PHASE3)
- Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD P 506 A CI brief — competitive landscape report
- PD P 506 A updates RSS · CI watch RSS
- photonamic GmbH & Co. KG portfolio CI
Frequently asked questions about PD P 506 A
What is PD P 506 A?
Who makes PD P 506 A?
Is PD P 506 A also known as anything else?
What development phase is PD P 506 A in?
Related
- Manufacturer: photonamic GmbH & Co. KG — full pipeline
- Also known as: Alacare®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing